Amarin Corp Plc (AMRN)

[HDGabor]

r-

What about a patient with TG 600 who also fits the REDUCE-IT profile (except for VHTG)?

After we retire gV then we can fight Lovaza.

What should happen in an ideal world is that Lovaza should be banned, period. If not banned, it should only be prescribed with those with > 500 and no CVD risk. Good luck finding those folks.

My layman view: Risk of pancreatitis is more important than CVD risk in case of VHTG (TG > 500). The primary aim of the treatment is to avoid / prevent pancreatitis, decrease the TG level. For this, Lovaza is superior to Vascepa.

Below TG 500, risk of pancreatitis does not exist anymore, the focus is the CVD risk ... Vascepa is the solution.

Both - Vascepa and Lovaza - have the function:
- pancreatitis: Lovaza
- CVD risk: Vascepa
(In case of TG > 500 and CVD risk, the CVD risk "does not" matter").

Best,
G